PDS Biotechnology Corp (PDSB)

5.15
+0.59(+12.94%)
After Hours
5.14
-0.01(-0.19%)
- Real-time Data
  • Volume:
    365,374
  • Day's Range:
    4.47 - 5.26
  • 52 wk Range:
    3.47 - 17.85

PDSB Overview

Prev. Close
4.56
Day's Range
4.47-5.26
Revenue
-
Open
4.47
52 wk Range
3.47-17.85
EPS
-0.82
Volume
365,374
Market Cap
146.52M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
262,786
P/E Ratio
-
Beta
2.37
1-Year Change
8.19%
Shares Outstanding
28,450,894
Next Earnings Date
Aug 04, 2022
What is your sentiment on PDS Biotech?
or
Market is currently closed. Voting is open during market hours.

PDS Biotechnology Corp News

PDS Biotechnology Corp Analysis

PDS Biotechnology Corp Company Profile

PDS Biotechnology Corp Company Profile

Employees
15

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is focused on developing a growing pipeline of cancer immunotherapy candidates and infectious disease vaccine candidates designed to overcome the limitations of immunotherapy technologies. It owns Versamune, a T-cell activating platform designed to train the immune system to destroy disease. Its lead product candidate, PDS0101, which combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products is all administered by subcutaneous injection. DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on agonist antigens from the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell
  • You have about 8 days to get in before the ASCO news comes out. And it's real big
    0
    • Researchers in Brazil warn that corona recoverers may re-infect the Brazilian variant. According to the study, the antibodies in the blood of recoverers infected with previous corona strains had a 6-fold reduced ability to neutralize the Brazilian strain.
      1
      • This company has little open news, do you know what they have in the pipe-line?
        0
        • It's back! This is going to the moon and beyond soon. Get in while you can.
          1
          • You better have a great earnings report. Real shady offering your stock at a lower price than listed. I'd sell immediately if I wouldn't lose so much money right now.
            0
            • Well ***happened today? It's up when the market is down and down when the market is up
              0
              • Got in at 4.24 today. Has potential to shoot high. Going to be a long term hold hopefully with steady growth.
                0
                • Anyone who is experienced have any thoughts for PDSB next week? Im in at 3.86
                  0
                  • I'm ready for the $2.00 movement!
                    0
                    • Finally some movement.. Lets go $2
                      0